CPRX - Insider Unloading: Molly Harper Sells $201K Worth Of Catalyst Pharmaceuticals Shares | Benzinga
A substantial insider sell was reported on December 19, by Molly Harper, Board Member at Catalyst Pharmaceuticals (NASDAQ:CPRX), based on the recent SEC filing.
What Happened: Harper opted to sell 14,000 shares of Catalyst Pharmaceuticals, according to a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The transaction's total worth stands at $201,420.
Tracking the Wednesday's morning session, Catalyst Pharmaceuticals shares are trading at $14.5, showing a down of 1.56%.
All You Need to Know About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Understanding the Numbers: Catalyst Pharmaceuticals's Finances
Revenue Growth: Catalyst Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 79.39%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth ...